Product
Supplier
Encyclopedia
Inquiry
Lipo-C      10ml buy - large image1
Lipo-C      10ml buy - image1
Lipo-C      10ml buy - image2
Lipo-C      10ml buy - image3
Lipo-C      10ml buy - image4
Lipo-C      10ml buy - image5
Lipo-C      10ml buy - image6

Lipo-C 10ml

TDS 29 Inquiries

Unit Price:

$50/UNIT FOB

Get Latest Price
CAS No.:

204656-20-2

Grade:

Research Grade

Content:

99%

Port:

Shenzhen

Brand:

lq

Packaging:

10mg

Price valid (until):

2027-02-25

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Retatrutide,Tirzepatide,Semaglutide,GHK-CU

  • Product Description

  • Seller Information

  • Inquiry History

  • Description
    Items Specifications
    CAS Number 204656-20-2
    Product Name Synthetic Peptide Raw Material
    Appearance White lyophilized powder
    HPLC Purity ≥99%
    Grade Research Grade, Non-pyrogenic
    Standard Package 0.1mg / 1mg / 5mg per glass vial
    Storage Condition Sealed, -20℃, avoid light & repeated freeze-thaw

    

    Core Product Advantages For Laboratory Research

    1. Ultra-High Purity & Traceable Batch Quality Inspection

      Each production batch undergoes dual quality testing via HPLC and mass spectrometry before delivery. Complete English batch COA documents including HPLC purity chromatogram, MS molecular weight verification report, endotoxin detection record and visual appearance inspection sheet are attached with each shipment, which can be directly filed for academic paper data certification and internal laboratory archive management. Miscellaneous peptide impurity content is controlled below 2%, effectively avoiding experimental data deviation caused by impure peptide fragments.
    2. Low-Temperature Vacuum Lyophilization For Stable Bioactivity

      Advanced vacuum freeze-drying craft is adopted instead of high-temperature drying, which fully retains the natural secondary spatial structure of peptide molecules without denaturation. The lyophilized solid powder greatly extends storage period compared with liquid peptide reagents, and maintains stable biological activity after long-term low-temperature preservation, ensuring consistent experimental results in long-cycle continuous comparative tests.
    3. Low Cytotoxicity & Broad Laboratory Application Compatibility

      This synthetic peptide features low cytotoxicity to mammalian cells, suitable for co-culture with epithelial cells, immune cells and tumor cell lines. It can be directly dissolved in common laboratory aqueous buffers and serum-free cell culture medium without additional organic solvent additives that may interfere with cell viability, simplifying experimental preparation steps and reducing external variable interference.
    4. Independent Vacuum Sealed Small-Vial Packaging

      Standard micro-dose single vial vacuum sealing design prevents cross-contamination between different experimental groups. Each glass vial is sealed with butyl rubber stopper and aluminum cover under vacuum state to isolate air and water vapor, slowing down peptide oxidation and degradation. Small research teams with limited sample consumption can use one vial per experiment to prevent raw material waste and activity attenuation caused by repeated opening of bulk packages.
    5. Neutral Customized Packaging & Full English Document Support

      We support neutral blank vial packaging without factory logos for confidential laboratory internal research projects. All batch inspection documents adopt standard international laboratory English format, no manual translation or format adjustment is required for filing in overseas universities and independent research institutions. We can also adjust peptide dosage and packaging specifications according to customers’ unique experimental schemes.

    Permitted In-Vitro Laboratory Research Application Scope

    This peptide raw material can only be operated by professionally trained laboratory technicians inside biosafety cabinets, and all usage scenarios are limited to in-vitro cell and biochemical testing experiments, with zero permission for any human-related usage. Main applicable research directions are listed below:
    • In-vitro cell proliferation, migration and differentiation induction comparative experiments
    • Basic research on innate immune cell signal transduction and cytokine secretion regulation
    • Exploration of epithelial and mucosal tissue barrier repair biological mechanisms
    • Construction of in-vitro microbial infection cell models for pathogenic mechanism study
    • Comparative cytotoxicity testing of synthetic peptide on various mammalian cell lines
    • Optimization of peptide additive formulas for serum-free cell culture medium
    Shop Lipo-C      10ml-Detailed Image 1
    Shop Lipo-C      10ml-Detailed Image 2
    Shop Lipo-C      10ml-Detailed Image 3
    Shop Lipo-C      10ml-Detailed Image 4
    Shop Lipo-C      10ml-Detailed Image 5
    Shop Lipo-C      10ml-Detailed Image 6
    Shop Lipo-C      10ml-Detailed Image 7
    Shop Lipo-C      10ml-Detailed Image 8
    Shop Lipo-C      10ml-Detailed Image 9
    Shop Lipo-C      10ml-Detailed Image 10
    Shop Lipo-C      10ml-Detailed Image 11
    Shop Lipo-C      10ml-Detailed Image 12
    Shop Lipo-C      10ml-Detailed Image 13
    Shop Lipo-C      10ml-Detailed Image 14
    Shop Lipo-C      10ml-Detailed Image 15
    Shop Lipo-C      10ml-Detailed Image 16
    Shop Lipo-C      10ml-Detailed Image 17
    ECHEMI Editorial Reference
    Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
    Liraglutide is characterized as a white to almost white powder. It is freely soluble in aqueous base solutions (> 270 mg/mL), but its water solubility decreases below pH 7 and reaches its lowest level at pH 4-5 (approximately 0.05 mg/mL). Solubility increases marginally at pH 2.5 where it is very slightly soluble (≤ 0.8 mg/mL). Liraglutide is soluble in methanol (68 mg/mL) and very slightly soluble in ethanol (1.1 mg/mL). The isoelectric point of liraglutide is approximately 4.9. The pH of a 1 mg/mL aqueous solution of drug substance is approximately 9.3.
    ChEBI: Liraglutide, a lipopeptide and polypeptide, is an analogue of human GLP-1 in which the lysine residue at position 27 is replaced by arginine and a hexadecanoyl group attached to the remaining lysine via a glutamic acid spacer. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Liraglutide functions as a glucagon-like peptide-1 receptor agonist and serves as a neuroprotective agent.
    Liraglutide is GLP-1(1–37) modified at Ly: the -amino group is acylated with an (N-hexadecanoyl)glutam- -yl moiety that noncovalently but avidly binds tohuman serum albumin. (Also, Lys is conservatively replacedwith Arg.) These changes provide for a greatly extendedserum t12 of~10 to 15 hours after sc administration(0.6–1.8 mg), allowing for once-daily dosing.Liraglutide (Victoza, Novo Nordisk) is awaiting approvalby the FDA, EMEA, and the Koˉ roˉ -shoˉ (Japan).
    Liraglutide peptide is a single, non-glycosylated polypeptide chain containing 31 amino acids, having a molecular mass of 3751 Dalton and a Molecular formula of C172H265N43O51.

    Certificates
    • Lipo-C      10ml Certificates 1 TDS

    Basic Info
    Product Name:

    Liraglutide

    Other Name:

    Liraglutide;Glycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-;Liraglutida;Liraglutida [inn-spanish];Liraglutide [usan:inn];Liraglutidum;Liraglutidum [inn-latin];N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide

    CAS No.:

    204656-20-2

    Molecular Formula:

    C172H265N43O51

    InChIKeys:

    YSDQQAXHVYUZIW-VTFFJMQZNA-N

    Molecular Weight:

    3751.202

    Exact Mass:

    3748.95000

    EC Number:

    810-818-7

    Color/Form:

    White to Off-White

    Characteristics
    PSA:

    1513.76000

    XLogP3:

    6.12960

    Melting Point:

    >182°C (dec.)

    Critical Temperature & Pressure:

    Refrigerator

    Research
    Class:

    GLP-1 receptor agonist (acylated GLP-1 analog, 31-amino-acid peptide)

    Status:

    FDA-approved (Victoza 2010, Saxenda 2014 for obesity)

    Mechanism:

    A 31-amino-acid GLP-1 analog with a C16 fatty-acid chain (palmitoyl) attached to Lys26 via a gamma-glutamic acid spacer. This fatty-acid modification enables reversible binding to serum albumin, extending the half-life to ~13 hours and allowing once-daily dosing. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.

    EC50 (GLP1R Ec50):

    ~10 nM

    Source:

    DrugBank: DB06655; Knudsen LB, et al. J Med Chem. 2000;43(9):1664-1669.DOI

    Clinical Development:

    NCT00781922; NCT01272219

    FDA:

    Victoza, Saxenda (approved 2010-01-25)

    References
    ChEMBL:

    CHEMBL1213363

    DrugBank:

    DB06655

    KEGG DRUG:

    D09199

    PubChem:

    PubChem

    Disclaimer:

    Liraglutide is FDA-approved as a prescription medicine (Victoza for T2DM, Saxenda for obesity). This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

    Hazard Identification

    Classification of the substance or mixture

    Carcinogenicity, Category 2

    Reproductive toxicity, Category 2

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Warning

    Hazard statement(s)

    H351 Suspected of causing cancer

    H361 Suspected of damaging fertility or the unborn child

    Precautionary statement(s)
    Prevention

    P203 Obtain, read and follow all safety instructions before use.

    P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...

    Response

    P318 IF exposed or concerned, get medical advice.

    Storage

    P405 Store locked up.

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Retatrutide,Tirzepatide,Semaglutide,GHK-CU

    Location:

    Plot 1, No. 205 Tongbao Road, Jiangdong Subdistrict, Yiwu City, Jinhua City, Zhejiang Province

    Payment Terms:

    TT against B/L draft before shipment,100% TT in advance

    Year of Establishment:

    2026

  • Inquiry History
    29 Inquiries
    Country Product Purchase Quantity Date Posted
    India

    China factory wholesale price supply high purity 99% cas 204656-20-2 Liraglutide injection

    50 KG Sep 30, 2023
    India

    Liraglutide

    1.00 KG Oct 8, 2024
    India

    Liraglutide-USP

    150.00 G Oct 10, 2023
    United Kingdom

    Liraglutide

    20 MG Jul 8, 2026
    United States

    Mic (Lipo C with B12), VIP, Ss31, glutathione and, Reta

    50 MG Mar 4, 2026
    India

    liraglutide

    1 KG Feb 25, 2026
    United States

    liraglutide

    Jan 21, 2026
    United States

    liraglutide

    1 MT Nov 22, 2025
    Reunion Island

    Liraglutide

    1 G Apr 14, 2025
    United States

    Liraglut

    1 MT Feb 9, 2025
    Israel

    Liraglutide

    1 G Aug 26, 2024
    India

    Liraglutide

    10 G Jun 26, 2024
    India

    Liraglutide

    100 G Mar 4, 2024
    United States

    Semaglutide Liraglutide powder

    10 G Feb 20, 2024
    United States

    MIC

    2 MT May 20, 2026
    Canada

    Liraglutide

    1 KG Dec 8, 2025
    Brazil

    Liraglutida

    1 G Sep 29, 2025
    United States

    Liraglutide

    1 KG Aug 13, 2025
    Sweden

    liraglutide

    1 KG Aug 4, 2025
    Pakistan

    liraglutide injection

    50 KG Jan 21, 2025
    • 1
    • 2
    • Go to Page Go
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.